Home Biosimilar Antibodies Apoptosis PD-1/PD-L1 Cemiplimab (anti-PD-1)
For research use only. Not for use in humans.

Cemiplimab (anti-PD-1)

Synonyms: CD279,hPD-l

Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.

Cemiplimab (anti-PD-1)

Click to purchase the isotype control of Cemiplimab (anti-PD-1)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99.3% Protein concentration: 5 mg/ml Endotoxin Level: <1 EU/mg
99.3

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 14
BMS-1 13
BMS-202 28
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 5
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.
Features
Human IgG4
In vitro

In cell-based assays, REGN2810 reverses PD-1-dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells.
Cell Research

Objective: T cell activation bioassays
Cells: Jurkat/AP-1-Luc/hPD-1 cells, HEK293/hCD20 cells, HEK293/hCD20/hPD-L1 cells
Concentrations: 0.1 pM-0.1 μM
Incubation Time: 4-6 h
Method: Antigenpresenting cell (APC)-like HEK293 cells are generated by lentiviral transduction of human CD20 and human PD-L1. T-cell receptor (TCR) activation is achieved by an antiCD3 x anti-CD20 bispecific antibody. To generate a dose response curve for anti-CD3 x anti-CD20, the bispecific molecule is serially diluted and tested with 50,000/well Jurkat/AP-1-Luc/hPD-1 and 10,000/well HEK293/hCD20 or HEK293/hCD20/hPD-L1 cells in a 96-well plate. Serially diluted REGN2810 is tested under similar conditions in the presence of a fixed concentration of anti-CD3 x anti-CD20 (100 pM). Plates are incubated at 37°C for 4-6 hours.
Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

Objective: T cell activation bioassays
Cells: HEK293/hCD20/hPD-L1 cells, CD4+ T cells, HEK293/hCD20/hPD-L1 cells
Concentrations: 0.1 pM-0.1 μM
Incubation Time: 72 h
Method: HEK293/hCD20/hPD-L1 cells are treated with 50 mg/mL mitomycin C for 30 minutes at 37°C to inhibit proliferation. Serially diluted REGN2810 is incubated with 50,000/well preactivated CD4+ T cells and 25,000/well of HEK293/hCD20/hPD-L1 cells in the presence of 2 nM anti-CD3 x anti-CD20 bispecific antibody in a 96-well plate for 72 hours.
Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)
In vivo

Cemiplimab (REGN2810) binds the humanized PD-1 receptor and inhibits growth of MC38 murine tumors in human PD-1 knock-in mice. As REGN2810 binds to cynomolgus monkey PD-1 with high affinity, pharmacokinetic and toxicologic assessment of REGN2810 is performed in cynomolgus monkeys. High doses of REGN2810 are well tolerated, without adverse immune-related effects.
Animal Research

Objective: MC38 mouse colon carcinoma
Animal Models: adult human PD-1 knock-in mice
Formulation: --
Dosages: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
Administration: i.p.
Reference: https://pubmed.ncbi.nlm.nih.gov/28265006

Objective: pharmacokinetic (PK) study
Animal Models: cynomolgus monkeys (Macaca fascicularis)
Formulation: --
Dosages: 1 mg/kg, 5 mg/kg, 15 mg/kg
Administration: i.v.
Reference: https://pubmed.ncbi.nlm.nih.gov/28265006

Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)
References

Product Details

CAS No. 1801342-60-8
Isotype Human IgG4
Source HEK293
Sterility 0.2 μM filtered
Formulation PBS buffer. Contains no stabilizers or preservatives
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07365839 NOT_YET_RECRUITING Drug: Arm 1 cemiplimab|Drug: Arm 2 cemiplimab and fianlimab Hepatocellular Carcinoma Virginia Commonwealth University 2026-10-01 PHASE1
NCT07195734 RECRUITING Drug: Carboplatin|Drug: Cisplatin|Drug: Paclitaxel Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Locally Recurrent Head and Neck Squamous Cell Carcinoma; Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma; Locally Recurrent Laryngeal Squamous Cell Carcinoma; Locally Recurrent Oral Cavity Squamous Cell Carcinoma; Locally Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage II Laryngeal Cancer AJCC v8; Stage II Lip and Oral Cavity Cancer AJCC v8; Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 National Cancer Institute (NCI) 2026-04-24 PHASE2
NCT07567469 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Cemiplimab+Fianlimab Fixed Dose Combi High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma Regeneron Pharmaceuticals 2026-08-31 PHASE1; PHASE2
NCT06794775 RECRUITING Drug: Nivolumab|Drug: Nivolumab + Ipilimumab Malignant Melanoma Stage III Hildur Helgadottir 2025-07-10 PHASE3
NCT06917573 RECRUITING Drug: Cemiplimab|Drug: Carboplatin|Drug: Paclitaxel Non Small Cell Lung Cancer Metastatic; Lung Diseases; Stage IV Non-small Cell Lung Cancer; Stage III Non-small Cell Lung Cancer; Respiratory Tract Neoplasms; Thoracic Neoplasms Fundación GECP 2025-07-29 PHASE2
NCT07346196 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Fianlimab|Drug: Carboplatin|Drug: Pac Squamous Cell Carcinoma University of Chicago 2027-02-07 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-25)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.